Abstract
The metabolic syndrome is strongly associated with insulin resistance and visceral obesity and consists of a constellation of factors such as diabetes, hypertension, dyslipidemia and non-alcoholic steatohepatits, which could in concert increase the risk for cardiovascular diseases (CVD). CVD, including myocardial infarction and stroke, is one of the leading causes of morbidity and mortality in the developed countries. Atherothrombosis, characterized by atherosclerotic plaque disruption and subsequent thrombus formation, contributes to the pathogenesis of CVD. Although therapeutic strategy for CVD has been progressed with anti-platelet and anti-thrombotic therapy, statins, and inhibitors of renin-angiotensin system, current therapeutic options may have therapeutic limitations because a substantial number of patients still experience CVD. Therefore, to develop novel therapeutic strategies that specifically target CVD is intensely desired. We and the others, have recently found that pigment epithelium-derived factor (PEDF), one of the serpins with neuronal differentiative activity, has insulin-sensitizing actions in the liver and adipose tissues, and exerts anti-inflammatory, anti-thrombogenic and vasculoprotective properties in vivo, thereby playing a protective role against the development and progression of the metabolic syndrome and CVD. In addition, serum levels of PEDF have been shown to increase in patients with visceral obesity, insulin resistance, diabetes, chronic kidney disease and CVD, thus being a novel biomarker of various cardiometabolic disorders. This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders.
Keywords: Atherosclerosis, cardiometabolic disorders, oxidative stress, PEDF.
Current Pharmaceutical Design
Title:Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Volume: 20 Issue: 14
Author(s): Sho-ichi Yamagishi and Takanori Matsui
Affiliation:
Keywords: Atherosclerosis, cardiometabolic disorders, oxidative stress, PEDF.
Abstract: The metabolic syndrome is strongly associated with insulin resistance and visceral obesity and consists of a constellation of factors such as diabetes, hypertension, dyslipidemia and non-alcoholic steatohepatits, which could in concert increase the risk for cardiovascular diseases (CVD). CVD, including myocardial infarction and stroke, is one of the leading causes of morbidity and mortality in the developed countries. Atherothrombosis, characterized by atherosclerotic plaque disruption and subsequent thrombus formation, contributes to the pathogenesis of CVD. Although therapeutic strategy for CVD has been progressed with anti-platelet and anti-thrombotic therapy, statins, and inhibitors of renin-angiotensin system, current therapeutic options may have therapeutic limitations because a substantial number of patients still experience CVD. Therefore, to develop novel therapeutic strategies that specifically target CVD is intensely desired. We and the others, have recently found that pigment epithelium-derived factor (PEDF), one of the serpins with neuronal differentiative activity, has insulin-sensitizing actions in the liver and adipose tissues, and exerts anti-inflammatory, anti-thrombogenic and vasculoprotective properties in vivo, thereby playing a protective role against the development and progression of the metabolic syndrome and CVD. In addition, serum levels of PEDF have been shown to increase in patients with visceral obesity, insulin resistance, diabetes, chronic kidney disease and CVD, thus being a novel biomarker of various cardiometabolic disorders. This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi and Matsui Takanori, Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990473
DOI https://dx.doi.org/10.2174/13816128113199990473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insight on the Body Fat Lowering Effect of 3,5-Diiodo-L-Thyronine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Control of Blood Pressure in the Community: An Unsolved Problem
Current Pharmaceutical Design Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Clinically Significant Proteinuria Following the Administration of Sirolimus to Renal Transplant Recipients
Drug Metabolism Letters Effects of Cholinergic Enhancing Drugs on Cholinergic Transporters in the Brain and Peripheral Blood Lymphocytes of Spontaneously Hypertensive Rats
Current Alzheimer Research Obesity Therapy: How and Why?
Current Medicinal Chemistry Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Are Catechins, Polyphenols in Tea, Good for Your Health?
Current Nutrition & Food Science Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Structure and Inhibitor Binding Mechanisms of 11β -Hydroxysteroid Dehydrogenase Type 1
Current Chemical Biology Targeted-Therapy in Advanced Renal Cell Carcinoma
Current Medicinal Chemistry Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research Na+/Ca2+ Exchange Inhibitors: A New Class of Calcium Regulators
Cardiovascular & Hematological Disorders-Drug Targets Animal Models of Obesity and Metabolic Syndrome: Potential Tools for Alzheimers Disease Research
Current Alzheimer Research Nutraceutical Targeting of Placental Synthesis of Soluble Fms-Like Tyrosine Kinase- 1 (sFlt-1) as Strategy for Preventing and Controlling Pre-eclampsia
Current Pharmaceutical Design Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Identifying the Metabolic Syndrome in Obese Children and Adolescents: Do Age and Definition Matter?
Current Clinical Pharmacology A Novel Method Aimed at Counteracting the Side Effects Caused by Prostaglandin E<sub>2</sub> Deficiency During Non-Steroidal Anti-Inflammatory Drug Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effects of Senna didymobotrya Root Extract and Compounds on Tritoninduced Hyperlipidaemic Rats and Differentiation of 3T3-Li Preadipocytes
The Natural Products Journal